Karius is revolutionizing the infectious disease diagnostic process by empowering healthcare providers through rapid, accurate and broad detection of pathogens associated with life-threatening infections.
Our “Direct-to-Library” process skips DNA extraction by preparing the sequencing library directly from the sample. By limiting hands-on time and building rigorous quality measures into every step, we minimize the potential for false positives or environmental contamination, which are typical challenges for metagenomic technology.
Our continuously updated, clinical-grade database powers all Karius offerings, ensuring accurate microbial detection to support informed patient care. It contains over 20,000 references curated by our team of PhD biostatisticians, data engineers, and medical directors. Microbial cell-free DNA sequences from patient samples are compared to this database, which includes more than 1,000 human pathogens covered by our commercial plasma test.
Advanced machine learning algorithms allow analysis of complex genomic data in real time. Our proprietary reference genome databases are constantly refined as more data becomes available.
Karius Spectrum is a blood test based on metagenomic sequencing of plasma microbial cell-free DNA that can detect over 1,000 pathogens associated with deep-seated and difficult-to-diagnose systemic infections caused by fungi, bacteria, parasites, and DNA viruses.
Our goal is for Karius' technology to have a transformative impact on healthcare by enhancing clinical outcomes in both the clinical trial and real-world settings. Working with our biopharma partners and healthcare providers, we are dedicated to advancing the development of novel therapies, helping clinicians rapidly identify optimal treatments, and enabling patients to stay on therapy.
